Litigation Details for Allergan USA, Inc. v. MSN Laboratories Private Limited (D. Del. 2019)
✉ Email this page to a colleague
Allergan USA, Inc. v. MSN Laboratories Private Limited (D. Del. 2019)
| Docket | ⤷ Sign Up | Date Filed | 2019-09-13 |
| Court | District Court, D. Delaware | Date Terminated | |
| Cause | 35:271 Patent Infringement | Assigned To | Richard Gibson Andrews |
| Jury Demand | None | Referred To | |
| Patents | 10,188,632; 7,741,356; 7,786,158; 8,344,011; 9,115,091; 9,364,489; 9,675,587; 9,789,125 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in Allergan USA, Inc. v. MSN Laboratories Private Limited
The small molecule drug covered by the patents cited in this case is ⤷ Sign Up .
Details for Allergan USA, Inc. v. MSN Laboratories Private Limited (D. Del. 2019)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2022-10-20 | 418 | Opinion - Memorandum Opinion | infringement of U.S. Patent Nos. 9,675,587 (the "'587 Patent") and 10,188,632 (the "'…are the patents at issue (i.e., the '291 Patent, the '587 Patent, the '632 Patent, '…627 Patent, and '516 Patent), the prosecution histories of patent applications in the patent family…prosecuted patents belonging to the patent family at issue. Allergan later obtained U.S. Patent Nos. 11,…alleging that the '516 Patent, the '627 Patent, and the '291 Patent are unenforceable under | External link to document |
| 2022-10-20 | 420 | Opinion - Memorandum Opinion | infringement of U.S. Patent Nos. 9,675,587 (the "'587 Patent") and 10,188,632 (the "'…prosecuted patents belonging to the patent family at issue. Allergan later obtained U.S. Patent Nos. 11,007,179…11,007,179 (the '"179 Patent"), 11,090,291 (the "'291 Patent"), and 11,160,792 (…asserting these patents were consolidated with this action. Allergan obtained U.S. Patent Nos. 11,… (the "'627 Patent") and 11,311,516 (the '"516 Patent") in January 2022 | External link to document |
| 2022-11-13 | 444 | Opinion - Memorandum Opinion | infringement of U.S. Patent Nos. 9,675,587 (the "'587 Patent") and 10,188,632 (the "'…prosecuted patents belonging to the patent family at issue. Allergan later obtained U.S. Patent Nos. 11,007,179…11,007,179 (the "'179 Patent"), 11,090,291 (the "'291 Patent"), and 11,160,792 (…asserting these patents were consolidated with this action. Allergan obtained U.S. Patent Nos. 11,229,627… (the '"627 Patent") and 11,311,516 (the "'516 Patent") in January 2022 | External link to document |
| 2023-09-27 | 483 | Opinion | )(IV) for U.S. Patent Nos. 9,675,587 (the '" 587 patent") and 10,188,632 (the "'…infringes U.S. Patent No. 11,229,627 (the "' 627 patent") and the '291 patent. (D.I. 461…prosecuted patents belonging to the patent family at issue. Allergan later obtained U.S . Patent Nos. 11…x27; 179 patent (JTX-002) when referring to the patent specification of the asserted patents. …x27; 516 patent (JTX-006 (' 516 patent), cl. 26) and claim 7 of the '1 79 patent do not list | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
